Settings
AGN [NYSE]
Allergan Inc.
IndexS&P 500 P/E53.11 EPS (ttm)4.29 Insider Own9.90% Shs Outstand297.90M Perf Week4.19%
Market Cap67.87B Forward P/E26.62 EPS next Y8.56 Insider Trans0.00% Shs Float297.34M Perf Month8.92%
Income1.30B PEG2.54 EPS next Q1.83 Inst Own91.60% Short Float0.79% Perf Quarter24.27%
Sales7.01B P/S9.68 EPS this Y17.60% Inst Trans-1.37% Short Ratio0.81 Perf Half Y34.05%
Book/sh23.95 P/B9.51 EPS next Y35.87% ROA11.80% Target Price218.47 Perf Year98.60%
Cash/sh14.05 P/C16.22 EPS next 5Y20.94% ROE19.30% 52W Range110.48 - 224.28 Perf YTD7.17%
Dividend0.20 P/FCF48.52 EPS past 5Y17.90% ROI15.70% 52W High1.58% Beta0.70
Dividend %0.09% Quick Ratio3.70 Sales past 5Y7.40% Gross Margin88.10% 52W Low106.23% ATR3.14
Employees11500 Current Ratio3.90 Sales Q/Q16.60% Oper. Margin30.80% RSI (14)72.51 Volatility1.37% 1.30%
OptionableYes Debt/Eq0.30 EPS Q/Q-6.40% Profit Margin18.50% Rel Volume0.59 Prev Close224.17
ShortableYes LT Debt/Eq0.29 EarningsFeb 03 BMO Payout4.60% Avg Volume2.89M Price227.83
Recom2.40 SMA205.48% SMA507.50% SMA20027.70% Volume1,714,294 Change1.63%
Dec-17-14Downgrade UBS Buy → Neutral $206 → $219
Dec-15-14Downgrade Stifel Buy → Hold
Oct-09-14Initiated Deutsche Bank Buy $215
Oct-01-14Upgrade Stifel Hold → Buy $200
Jul-22-14Upgrade UBS Neutral → Buy $180 → $200
Apr-28-14Downgrade Stifel Buy → Hold
Apr-22-14Downgrade Argus Buy → Hold
Mar-07-14Reiterated Barclays Equal Weight $95 → $130
Feb-07-14Reiterated Argus Buy $110 → $130
Jan-08-14Reiterated Argus Buy $110 → $125
Jan-07-14Initiated RBC Capital Mkts Outperform $131
Dec-20-13Reiterated UBS Buy $100 → $116
Dec-20-13Reiterated BMO Capital Markets Outperform $112 → $117
Oct-31-13Reiterated Argus Buy $118 → $110
Jun-25-13Reiterated Canaccord Genuity Hold $111 → $98
Jun-24-13Downgrade Deutsche Bank Buy → Hold
May-02-13Reiterated RBC Capital Mkts Outperform $123 → $119
Feb-06-13Reiterated Stifel Nicolaus Buy $110 → $118
Feb-06-13Reiterated Canaccord Genuity Hold $102 → $111
Jan-22-13Reiterated Canaccord Genuity Hold $101 → $102
Jan-26-15 09:41PM  Allergan sets up meeting to seek shareholder OK of Actavis acquisition at Los Angeles Times
05:30PM  Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC PR Newswire
05:30PM  Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC Business Wire
Jan-23-15 01:28AM  Davos: Why M&A won't go away at CNBC
Jan-22-15 06:26PM  Thursday's Market Recap Yahoo Finance Contributors
06:16PM  Lieff Cabraser Announces Class Action Litigation Against Allergan Inc. - AGN Business Wire
Jan-21-15 12:23PM  Hungry Actavis pauses to digest Allergan at Financial Times
12:09PM  Valeant chief Pearson admits 'miscalculation' in Allergan pursuit at Financial Times
09:55AM  Cramer's Stop Trading: ACT doesn't quit CNBC
06:00AM  This Giant Drug Firm Won't Invent Medicines. Investors Are Cheering at Forbes
Jan-20-15 05:21PM  UPDATE - AGN SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Involving Allergan, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 16, 2015 -- AGN GlobeNewswire
12:57PM  The Woman Who Is Posting Some Of The Hedge Fund World's Best Returns at Forbes
Jan-19-15 06:10PM  Roche to Acquire French Biotechnology Company Trophos - Analyst Blog Zacks
Jan-16-15 11:10AM  Hospira Submits Retacrit Regulatory Application to the FDA - Analyst Blog Zacks
Jan-15-15 10:30AM  Valeant Pharmaceuticals International -- Moody's revises Valeant outlook to positive, rates new notes B1 at Moody's
10:30AM  AstraZeneca Announces Encouraging Data from Brilinta Study - Analyst Blog Zacks
Jan-14-15 06:20PM  Roche to Acquire Up to 56% Interest in Foundation Medicine - Analyst Blog Zacks
05:35PM  Eli Lilly Inks Oncology Deals with Merck, Bristol-Myers - Analyst Blog Zacks
12:00PM  Farallon Capital raises stake in Allergan Market Realist
Jan-13-15 05:42PM  Top Cybersecurity Stock Qualys Gets Support at Investor's Business Daily
12:46PM  Valeant CEO: Allegations about our business not true CNBC
Jan-12-15 05:29PM  And Oil continues to fall... Yahoo Finance Blogs
04:18PM  ALLERGAN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
01:52PM  Celgene Says Q4 Earnings Beat, Sees Currency Impact at Investor's Business Daily
12:38PM  Actavis CEO: Good can come from activists CNBC
09:44AM  Actavis expects profit to beat expectations at MarketWatch
09:29AM  Actavis Profit to Beat Expectations at The Wall Street Journal
08:00AM  Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings PR Newswire
08:00AM  Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis Pending Acquisition of Allergan and Record Dates for Shareholder Meetings Business Wire
Jan-09-15 05:54PM  U.S. hedge fund manager Ackman makes $10 mln charity donation Reuters
Jan-08-15 06:06PM  Four Hot Growth Stocks To Put On Your Watch List at Investor's Business Daily
Jan-07-15 08:17AM  Bill Ackman: Herbalife is like Bernie Madoff at CNBC
07:05AM  Bill Ackman: Valeant could have raised bid for Allergan CNBC
Jan-06-15 06:17PM  Will Allergan Buy Help Actavis Extend Growth Streak? at Investor's Business Daily
11:11AM  ALERT: Rosen Law Firm Reminds Investors Who Sold Allergan Inc. Stock of the Important Class Action Deadline -- AGN GlobeNewswire
09:20AM  Ackman Rides Allergan Deal to Top of Hedge Fund Heap at Bloomberg
09:02AM  FDA approves first dermal filler to treat acne scarring Reuters
Jan-04-15 12:13PM  Deal of the year: Allergan at Financial Times
Jan-01-15 07:00AM  Our Take on the Fourth Quarter Morningstar
Dec-31-14 06:19AM  Three big hedge fund predictions for 2015 CNBC
05:00AM  Coffee and 4 other surprisingly great investments of 2014 at Fortune
Dec-29-14 04:13PM  AGN SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Involving Allergan, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 16, 2015 -- AGN Marketwired
03:47PM  Russell 1000's winners and losers CNBC
10:32AM  Law Offices of Howard G. Smith Announces Investigation on Behalf of Investors Who Sold Allergan, Inc. Common Stock Between February 25, 2014 and April 21, 2014 Business Wire
07:18AM  Bullish on biotech CNBC
Dec-24-14 01:10PM  Another Eye-Popping Twist in Allergan Deal: the Bankers' Fees at The Wall Street Journal
12:05PM  The Bests and the Bloopers from the Year in Deals at The Wall Street Journal
10:20AM  2014 Winning & losing hedgies CNBC
09:23AM  Cramer's Mad Dash: Pharma movers CNBC
Dec-23-14 12:32PM  SHAREHOLDER ALERT: Investors Who Sold Allergan, Inc. Common Stock Between February 25, 2014 and April 21, 2014 Are Encouraged to Contact Glancy Binkow & Goldberg LLP Business Wire
11:47AM  Oil Shakeout, Corporate Breakups Could Drive Merger And Acquisition Activity In 2015 at Forbes
Dec-18-14 07:10PM  Ackman Accused of Insider Trading in Allergan Shareholder Suit at Bloomberg
05:48PM  AGN SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Involving Allergan, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 16, 2015 -- AGN GlobeNewswire
05:39PM  Farallon Capital starts new position in Time Warner Inc. Market Realist
04:34PM  Lawsuit accuses Ackman, Valeant of insider trading in Allergan stock at Los Angeles Times
03:59PM  EQUITY ALERT: The Rosen Law Firm Announces the Filing of Securities Class Action on Behalf of Sellers of Allergan Inc. Stock From February 25, 2014 to April 21, 2014 Seeking to Recover Losses -- AGN GlobeNewswire
01:43PM  Elliott sells out its position in Allergan Market Realist
Dec-17-14 01:47PM  COTCHETT, PITRE & McCARTHY, LLP Files Class Action Lawsuit on Behalf of Persons Who Sold Allergan Stock Between February 25, 2014 and April 21, 2014 Business Wire
11:15AM  Deadline in Lawsuit for Certain Sellers of Allergan, Inc. (AGN) Shares Announced by Shareholders Foundation GlobeNewswire
11:06AM  Allergan downgraded by UBS Briefing.com
09:30AM  BOTTINI & BOTTINI, INC. Files Class Action Lawsuit On Behalf Of Persons Who Sold Allergan Stock Between February 25, 2014 And April 21, 2014 PR Newswire
Dec-16-14 10:12PM  Few Allergan execs to keep top jobs in Actavis takeover at Los Angeles Times
06:11PM  Great Stocks: Valeant Pharmaceuticals Near Buy Point at Investor's Business Daily
10:28AM  Actavis Unveils Management Changes at The Wall Street Journal
09:49AM  Activis to Replace Most Allergan Executives After Deal at Bloomberg
Dec-10-14 04:20PM  Roche (RHHBY) Presents Positive Data on Haemophilia Drug Zacks
08:16AM  The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan Zacks
Dec-09-14 06:15PM  Companies begging for activist to strike: Cramer CNBC
01:38PM  Where Could ValueAct Capital's New $1.5 Billion Go? Benzinga
08:41AM  Valeant puts dealmaking on hold to focus on the bottom line at Fortune
Dec-07-14 04:27PM  Reports: Merck in talks to buy Cubist at USA TODAY
Dec-06-14 04:06AM  My 2014 Healthcare Top 10 List at Forbes
Dec-05-14 04:49PM  Sanofi Buys Merck's Manufacturing Facility in Puerto Rico Zacks
12:48PM  Activist Investors Torn on Private Equity Partnerships at TheStreet
09:17AM  Goldman's Parker Calls Allergan Pursuit a 'One-time Opportunity' at TheStreet
Dec-03-14 06:53PM  Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now at TheStreet
03:45PM  AstraZeneca's (AZN) Iressa Accepted for Review in the U.S. Zacks
Dec-02-14 06:19PM  U.S. Stock Mutual Funds Led Advance In November at Investor's Business Daily
05:45PM  Actavis Launches Generic of Shire's ADHD Drug Intuniv Zacks
Dec-01-14 02:59PM  ALLERGAN INC Files SEC form 8-K, Other Events EDGAR Online
Nov-26-14 04:30PM  AstraZeneca/Amgen's Brodalumab Excels in Psoriasis Study Zacks
12:30PM  AstraZeneca's (AZN) Respiratory Drug Approved in the EU Zacks
08:59AM  Ackman's Pershing Square still holds 26.6 million Allergan shares Reuters
Nov-25-14 06:35PM  5 Ways CEOs Handle Activist Investors at The Wall Street Journal
08:00AM  JANA Partners adds a new position in Valeant Pharmaceuticals Market Realist
Nov-24-14 05:16PM  [$$] Salix Plans to Boost Size of Board at The Wall Street Journal
04:18PM  Taking Stock: McCracken on Smith & Nephew Deal Coming Back at Bloomberg
04:00PM  Viking Global Investors increases stakes in Allergan Market Realist
02:46PM  Investors Who Sold Allergan (AGN) Shares Between April 1, 2014 and April 21, 2014 May Contact Gardy & Notis, LLP Law Firm For Further Information PR Newswire
12:48PM  Actavis Plans Job Cuts, China Expansion for Allergan at Bloomberg
07:22AM  Cramer: When Can a Solid CEO Catch a Break? TheStreet
Nov-21-14 11:15PM  Review at Barrons.com
10:54PM  [$$] Charting the Market at Barrons.com
06:27PM  ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Business Wire
04:00PM  Amgen and AbbVie Strengthen Manufacturing Facilities in Asia Zacks
03:49PM  Podcast: Do Allergan, Actavis, and Ackman Hint at a Market Top? at The Wall Street Journal
08:26AM  Allergan deal sits well on Actavis chief's 'Monopoly board' at Financial Times
04:11AM  After losing out over Allergan, Valeant announces $2 billion buyback at Fortune
Nov-20-14 06:28PM  Ackman-Valeant Alliance Proved Unwieldy at The Wall Street Journal
12:13PM  [$$] Valeant Sets $2 Billion Buyback Plan at The Wall Street Journal
Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company also holds LiRIS Program, which is in Phase II trials for the treatment of interstitial cystitis/bladder pain syndrome. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. The company focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. It has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sherman Scott DExecutive Vice President, HRApr 22Option Exercise75.5810,000755,80018,223Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 22Sale163.0010,0001,630,0008,223Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 21Option Exercise73.044,500328,68012,723Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 21Sale139.854,500629,3258,223Apr 23 07:25 PM
INGRAM DOUGLAS SPresidentFeb 21Sale125.701961,044Feb 25 05:49 PM
LAVIGNE LOUIS J JRDirectorFeb 21Sale125.795,400679,2440Feb 24 07:59 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 19Option Exercise58.5523,0001,346,65029,401Feb 21 04:56 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 19Option Exercise40.1638,9001,562,22455,491Feb 21 04:59 PM
HUDSON DAWN EDirectorFeb 19Sale126.354,200530,68311,600Feb 21 05:14 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 19Sale126.3938,9004,916,49316,591Feb 21 04:59 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 19Sale126.6623,0002,913,1116,401Feb 21 04:56 PM
Sherman Scott DExecutive Vice President, HRFeb 18Option Exercise75.585,000377,90013,220Feb 19 02:44 PM
Sherman Scott DExecutive Vice President, HRFeb 18Sale125.745,000628,7008,220Feb 19 02:44 PM
INGRAM DOUGLAS SPresidentFeb 14Option Exercise55.9884,0004,701,90085,058Feb 19 02:41 PM
Sherman Scott DExecutive Vice President, HRFeb 14Sale124.761708,220Feb 19 02:44 PM
INGRAM DOUGLAS SPresidentFeb 14Sale124.4084,00010,449,4321,058Feb 19 02:41 PM
PYOTT DAVID E IChairman of the Board and CEOFeb 12Option Exercise36.15252,0009,109,800417,000Feb 13 05:49 PM
BARLOW JAMES FSR. VP, Corp. Controller (PAO)Feb 12Option Exercise65.9223,8751,573,76930,754Feb 13 05:54 PM
PYOTT DAVID E IChairman of the Board and CEOFeb 12Sale123.12252,00031,025,560165,000Feb 13 05:49 PM
BARLOW JAMES FSR. VP, Corp. Controller (PAO)Feb 12Sale123.5223,8752,949,0416,879Feb 13 05:54 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 11Option Exercise55.9817,000951,57523,401Feb 13 05:56 PM
LAVIGNE LOUIS J JRDirectorFeb 11Option Exercise55.2054,6003,014,01924,123Feb 13 05:59 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 11Sale121.8217,0002,070,9576,401Feb 13 05:56 PM
LAVIGNE LOUIS J JRDirectorFeb 11Sale122.3954,6006,682,69612,723Feb 13 05:59 PM
Sherman Scott DExecutive Vice President, HRFeb 10Option Exercise75.585,000377,90013,325Feb 11 08:41 PM
Sherman Scott DExecutive Vice President, HRFeb 10Sale120.005,000600,0008,325Feb 11 08:41 PM
Sherman Scott DExecutive Vice President, HRFeb 07Option Exercise73.044,500328,68012,825Feb 11 08:41 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 07Option Exercise64.47105,5006,801,585122,371Feb 11 08:37 PM
Sherman Scott DExecutive Vice President, HRFeb 07Sale118.554,500533,4848,325Feb 11 08:41 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 07Sale117.74105,50012,421,04316,871Feb 11 08:37 PM